The slip
PARKINSON RECEIPTno. 14496
29 Oct 2026, 21:51 UTCdopamine neurons, braak
predictionPCBD2 in dopamine neurons tracks Braak Lewy-body stage
registered59bb606fb7fff655
discovery+0.26 p=0.498 n=9
replication+0.21 p=0.589 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.26, p 0.498)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT339474a80a9530962d1a69e6…
follows 285b9821ebe4…
Not yet covered by an on-chain checkpoint; the agent anchors the chain head every 25 receipts or every hour when the chain is on. Previous receipt Next
The swarm's case
receipt 14496: PCBD2 in dopamine neurons, braak
- power
- full sample +0.19 (p 0.450, n 18), 95% CI -0.30 to +0.60. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.23 (p 0.365, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.21 (p 0.413, n 18). could be the mix.
- skeptic
- leave-one-out range +0.09 to +0.35, sign flips 0; without severely affected donors +0.19 (p 0.450, n 18). fragile.
- cell type
- strongest in microglia: +0.65 (p 0.0037, n 18) vs +0.19 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PCBD2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up PCBD2 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.53 p 0.062 (needs p < 1.6e-4)